Equities researchers at Stifel Nicolaus started coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a note issued to investors on Thursday, The Fly reports. The firm set a “buy” rating on the medical research company’s stock.

Several other analysts also recently issued reports on TMO. Needham & Company LLC increased their price objective on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Evercore ISI raised shares of Thermo Fisher Scientific to an “outperform” rating in a research report on Thursday. ValuEngine downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus price target of $314.45.

NYSE TMO traded up $0.82 during mid-day trading on Thursday, hitting $300.84. The company’s stock had a trading volume of 860,760 shares, compared to its average volume of 1,545,269. Thermo Fisher Scientific has a 52-week low of $208.34 and a 52-week high of $306.00. The stock’s fifty day simple moving average is $290.49 and its two-hundred day simple moving average is $284.42. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.80 and a quick ratio of 1.23. The firm has a market capitalization of $117.70 billion, a P/E ratio of 27.05, a price-to-earnings-growth ratio of 1.90 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. During the same quarter last year, the firm posted $2.62 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific will post 12.33 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a share repurchase program on Friday, November 8th that authorizes the company to buyback $2.50 million in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the completion of the transaction, the chief executive officer now owns 283,502 shares of the company’s stock, valued at $84,483,596. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the completion of the transaction, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at approximately $97,332,684.80. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of TMO. Nuveen Asset Management LLC lifted its stake in Thermo Fisher Scientific by 10,824.0% in the second quarter. Nuveen Asset Management LLC now owns 1,928,966 shares of the medical research company’s stock valued at $566,498,000 after buying an additional 1,911,308 shares during the last quarter. Jennison Associates LLC lifted its stake in Thermo Fisher Scientific by 2,589.9% in the second quarter. Jennison Associates LLC now owns 819,138 shares of the medical research company’s stock valued at $240,564,000 after buying an additional 788,686 shares during the last quarter. Putnam Investments LLC lifted its stake in Thermo Fisher Scientific by 2,645.9% in the second quarter. Putnam Investments LLC now owns 720,795 shares of the medical research company’s stock valued at $211,683,000 after buying an additional 694,545 shares during the last quarter. AQR Capital Management LLC lifted its stake in Thermo Fisher Scientific by 38.8% in the second quarter. AQR Capital Management LLC now owns 2,141,471 shares of the medical research company’s stock valued at $621,561,000 after buying an additional 598,230 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Thermo Fisher Scientific by 22.9% in the second quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after buying an additional 555,802 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Institutional Investors

The Fly

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.